|
FoundationOne assay could support treatment decisions
July 2015
EDIT CONNECT
SHARING OPTIONS:
CAMBRIDGE, Mass.—Foundation Medicine Inc. recently presented new data regarding FoundationOne, its
comprehensive genomic profiling assay, which revealed that the assay identified a high frequency of clinically relevant genomic alterations in pediatric
gliomas. Comprehensive genomic profiling was performed on tumor samples from 75 pediatric patients, and 89 percent of cases were found to have at least one
clinically relevant genomic alteration.
“There are few things as devastating to childhood as brain cancer,” said
Dr. Vincent Miller, Foundation Medicine's chief medical officer. “In addition to the symptoms of the disease, the treatment options can be
incredibly harsh on a child's developing body, making it that much more important to select therapies with the best therapeutic index. As this study
demonstrates, comprehensive genomic profiling can serve a key role in the oncologic care of these children, providing the potential to identify opportunities
for the optimal matching of treatment to disease severity.”
Code: Back |
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|